Zhong-Yin Zhang

USPTO Granted Patents = 14 (Patent Applications = 1)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 2.4

ph-index = 3

Forward Citations = 15(Granted Patents)

Location History:

Indianapolis, IN (US) (2014)
Carmel, IN (US) (2015 - 2018)
West Lafayette, IN (US) (2019 - 2023)

Company Filing History:

Purdue Research Foundation

patents

2 out of 2,931

University of Florida Research Foundation Inc

patents

4. 1 out of 4,127

Wisconsin Alumni Research Foundation

patents

where one patent can have more than one assignee

Years Active: 2014-2023

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11814396 - Sesquiterpenoid analogs (2023-11-14),

2. 11629130 - Lymphoid-specific tyrosine phosphatase (LYP) inhibitors (2023-04-18),

3. 11518770 - Sesquiterpenoid analogs (2022-12-06),

4. 11192850 - N-aryl oxamic acids (2021-12-07),

5. 10532977 - Small molecule inhibitors of protein tyrosine phosphatases and uses thereof (2020-01-14),

6. 10494332 - Protein tyrosine phosphatases or SHP2 inhibitors and uses thereof (2019-12-03),

7. 10092543 - Methods of treating autoimmune and/or glomerulonephritis-associated diseases using SHP2 inhibitors (2018-10-09),

8. 10072043 - Inhibitors of protein tyrosine phosphatases (2018-09-11),

9. 9844535 - SHP2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using SHP2 inhibitors (2017-12-19),

10. 9522881 - Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) (2016-12-20),

11. 9493436 - [object Object] (2016-11-15),

12. 9340574 - Inhibitors of protein tyrosine phosphatases (2016-05-17),

13. 9217012 - Inhibitors of protein tyrosine phosphatases (2015-12-22),

14. 8637684 - Tautomycetin and tautomycetin analog biosynthesis (2014-01-28),

Title: Innovations and Contributions of Zhong-Yin Zhang

Introduction

Zhong-Yin Zhang is a prominent inventor based in Carmel, IN (US), known for his significant contributions to the field of biochemistry and pharmacology. With a total of 14 patents, his work focuses on developing novel compounds that have the potential to treat various diseases, including cancers and autoimmune disorders.

Latest Patents

Zhong-Yin Zhang's latest patents include innovative sesquiterpenoid analogs, which are designed as SHP2 and/or POLE3 inhibitors for potential cancer treatment. These compounds not only show promise in targeting cancer cells but also serve as chemosensitization agents to enhance the effectiveness of DNA-damaging drugs. Another notable patent involves lymphoid-specific tyrosine phosphatase (LYP) inhibitors, which are aimed at treating diseases associated with the PTPN22 genetic polymorphism. These diseases include type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus, among others. The LYP inhibitors may also represent a novel class of cancer immunotherapy, with administration options including injection or oral intake.

Career Highlights

Throughout his career, Zhong-Yin Zhang has worked with esteemed institutions such as Indiana University and Purdue Research Foundation. His research has significantly advanced the understanding of biochemical pathways and therapeutic interventions.

Collaborations

Zhong-Yin Zhang has collaborated with notable colleagues, including Li-Fan Zeng and Sheng Zhang, contributing to a rich environment of innovation and discovery in his field.

Conclusion

Zhong-Yin Zhang's work exemplifies the impact of innovative research in developing new therapeutic strategies for complex diseases. His contributions continue to inspire advancements in medical science and treatment options.

This text is generated by artificial intelligence and may not be accurate.